--- title: "Teva's branded drugs carry the story as generics shrink" url: "https://aibio.space/companies/teva-pharmaceutical-industries/desk-view/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-31" tickers: "TASE:TEVA" summary: "Weltruza's approval and a refinancing round out a busy year. The 2027 Medicare price on Austedo is the number that matters most." --- Opinion Desk view by the aibio.space Teva desk. Updated October 22, 2026. Every figure links to its source. This is analysis, not a recommendation to trade. [How desk views are written](https://aibio.space/disclosures/). Teva Pharmaceutical Industries ยท Opinion 2026-10-22 # Teva's branded drugs carry the story as generics shrink Weltruza's approval and a refinancing round out a busy year. The 2027 Medicare price on Austedo is the number that matters most. ## The technology Teva is two companies in one. It is a large maker of generic drugs and biosimilars, and it is building a branded business in neuroscience and immunology. The branded side carries the growth. Austedo, Ajovy and Uzedy together had [more than $1 billion of second-quarter revenue](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm), up 43% in local currency, while global generics fell 15%. The pipeline is mostly made of known mechanisms in new forms. Weltruza puts olanzapine into a [monthly shot under the skin with no post-injection monitoring](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re). Duvakitug, partnered with Sanofi, blocks TL1A in ulcerative colitis and Crohn's disease. TEV '408 is a Teva-discovered antibody against IL-15. Ecopipam, bought with Emalex, is a D1 receptor blocker for Tourette syndrome. ## The odds Weltruza is approved, and ecopipam is under FDA review with a [target date late in the first quarter of 2027](https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-a-first-in-cl). The European Medicines Agency is also reviewing the olanzapine injection after [accepting the application in May 2026](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re), and the BioXcel film Teva bid for has an [FDA action date of Nov. 14](https://www.tevapharm.com/news-and-media/latest-news/tevaannouncesproposedacquisition-ofanovel-neuroscienceproductreinforcing-disciplined-business-deve/) for at-home use, pending the bankruptcy sale. Drugs that reach a filing are approved [90.6% of the time](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf), according to BIO, Informa and QLS data for 2011 to 2020, and 93.6% in rare diseases. Duvakitug is in four phase 3 trials. Its 44-week phase 2b maintenance data showed [58% clinical remission in ulcerative colitis at 900 mg](https://www.tevapharm.com/news-and-media/latest-news/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive-outcomes-in-new-phase-2b-data-for-ulc/), but without a placebo arm. The same BIO data put the odds of a phase 3 program reaching a filing at 57.8%. TEV '408 is earlier: its celiac study met its primary endpoint with a [confidence interval of 0.06 to 0.84](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti-il-15-antibody/), and only 28.9% of phase 2 drugs reach phase 3. ## The money Teva had [$3,655 million of cash and $16,593 million of debt](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) at June 30, 2026, for net debt of $12,938 million. Its ratio of debt to debt plus equity was 68%. Second-quarter free cash flow was $622 million, and 2026 guidance calls for $2.0 billion to $2.4 billion. The company is refinancing. In September it priced [about $4.9 billion of new senior notes](https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245dex991.htm) to redeem older notes, including series with coupons of 6.750% to 8.125%. All three major rating agencies have returned Teva to [investment grade](https://www.tevapharm.com/news-and-media/latest-news/teva-begins-trading-ordinary-shares-directly-on-the-nyse-marking-a-milestone-in-its-pivot-to-growth-stra/). Teva has also used outside money to fund research, including [$400 million from Blackstone Life Sciences](https://www.tevapharm.com/news-and-media/latest-news/teva-and-blackstone-life-sciences-announce-$400-million-strategic-growth-capital-agreement-to-advance-duv/) for duvakitug. ## The risks Austedo is the largest brand, and its [Medicare negotiated price takes effect on Jan. 1, 2027](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm). Teva's legal challenge to the negotiation program was [decided on appeal on Aug. 18](https://media.cadc.uscourts.gov/opinions/docs/2026/08/25-5425-2188755.pdf): the D.C. Circuit held that CMS may treat Austedo and Austedo XR as one drug and that the program does not deprive Teva of a protected property interest, and it sent a narrow question on the "bona fide marketing" requirement back to the lower court. The October agreement with the U.S. government on [Medicaid prices](https://www.tevapharm.com/news-and-media/latest-news/teva-statement-on-reaching-an-agreement-with-the-us-administration/) adds another pricing commitment whose terms are not public. Generics are shrinking as competition for lenalidomide grows, and the Emalex deal produced [$726 million of second-quarter expenses](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm), which pushed Teva to a GAAP loss. The funding deals with Blackstone and Royalty Pharma give away part of future sales. ## Our read Teva's story is now about whether a handful of branded drugs can grow faster than generics decline and federal pricing bites. The second quarter suggests they can for now. The next proof points are concrete: Weltruza's launch, the ecopipam decision and the first phase 3 data for duvakitug. The balance sheet is better than it was, and the refinancing pushes out maturities, but leverage is still high for a company in the middle of building a new business. We would weigh the 2027 Austedo price change heavily, since it hits the biggest single source of growth. --- Source page: https://aibio.space/companies/teva-pharmaceutical-industries/desk-view/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Teva's branded drugs carry the story as generics shrink", 2026-10-31, https://aibio.space/companies/teva-pharmaceutical-industries/desk-view/